From GlobeNewswire: 2025-05-21 09:15:00

GRI Bio, Inc. will host a live webcast on May 28th at 4:00 PM ET, featuring CEO Marc Hertz. The event will include a corporate overview, business outlook, and a Q&A session for investors to submit questions live. A replay of the webcast will be available on the company’s website for 90 days. GRI Bio focuses on developing therapies targeting Natural Killer T cells to treat inflammatory, fibrotic, and autoimmune diseases. Their lead program, GRI-0621, aims to treat idiopathic pulmonary fibrosis. The company also has a pipeline of diverse NKT agonists for systemic lupus erythematosus treatment.



Read more at GlobeNewswire: GRI Bio to Participate in the Virtual Investor Closing Bell